Journal Article10.1097/01.JCP.0000130557.08996.7A
A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features
Anthony J. Rothschild,Douglas J. Williamson,Mauricio Tohen,Alan F. Schatzberg,Scott W. Andersen,Luann E. Van Campen,Todd M. Sanger,Gary D. Tollefson +7 more
142
TL;DR: Patients with major depression with psychotic features treated with OLZ monotherapy did not demonstrate significant depressive symptom improvement compared with placebo in either trial; however, an olanzapine/fluoxetine combination was associated with significant improvement comparedwith placebo in one trial and was well tolerated.
read more
Abstract: :The purpose of this study was to compare the efficacy and safety of olanzapine (OLZ) monotherapy and an olanzapine/fluoxetine combination (OFC) with placebo (PLA) for unipolar major depression with psychotic features. Under a single protocol, two 8-week, double-blind trials were conducted a
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders
Gin S Malhi,Darryl Bassett,Philip Boyce,Richard A. Bryant,Paul B. Fitzgerald,Kristina Fritz,Malcolm Hopwood,Bill Lyndon,Roger T. Mulder,Greg Murray,Richard J Porter,Ajeet B. Singh +11 more
TL;DR: The Mood Disorder CPG is the first Clinical Practice Guideline to address both depressive and bipolar disorders and provides up-to-date recommendations and guidance within an evidence-based framework, supplemented by expert clinical consensus.
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.
TL;DR: A diversity of multi-target strategies are proposed for the more efficacious and rapid control of core and co-morbid symptoms of depression, together with improved tolerance relative to currently available agents.
560
The medical management of depression
TL;DR: Treatment with antidepressant and adjunctive medications and prevention of future episodes of major depression are discussed in this article.
423
Therapeutic options for treatment-resistant depression.
TL;DR: Despite an increasing variety of choices for the treatment of TRD, this condition remains universally undefined and represents an area of unmet medical need.
207
References
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
TL;DR: The response to placebo in published trials of antidepressant medication for MDD is highly variable and often substantial and has increased significantly in recent years, as has the response to medication.
1.1K
Radioreceptor binding profile of the atypical antipsychotic olanzapine
Frank P. Bymaster,David O. Calligaro,Julie F. Falcone,Richard D Marsh,Nicholas A. Moore,Nicholas C Tye,Philip Seeman,David T. Wong +7 more
TL;DR: The receptor binding profile of olanzapine is consistent with the antidopaminergic, antiserotonergic, and antimuscarinic activity observed in animal models and predicts atypical antipsychotic activity in man.
1.1K
Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study
Mauricio Tohen,T. Jacobs,S. L. Grundy,Susan L. McElroy,Michael C. Banov,Philip G. Janicak,Todd M. Sanger,R.C. Risser,Fan Zhang,V. Toma,Judith Francis,Gary D. Tollefson,Alan Breier +12 more
TL;DR: Olanzapine demonstrated greater efficacy than placebo in the treatment of acute bipolar mania and was generally well tolerated.
579
A novel augmentation strategy for treating resistant major depression.
Richard C. Shelton,G.D. Tollefson,Mauricio Tohen,Stephen M. Stahl,Kimberley S. Gannon,T. Jacobs,William R. Buras,Frank P. Bymaster,Wei Zhang,Kimberley A. Spencer,Peter D. Feldman,Herbert Y. Meltzer +11 more
TL;DR: Olanzapine plus fluoxetine demonstrated superior efficacy for treating resistant depression compared to either agent alone.
541
The pharmacological treatment of delusional depression.
Duane G. Spiker,J C Weiss,R S Dealy,Griffin Sj,Israel Hanin,John F. Neil,James M. Perel,Rossi Aj,Paul H. Soloff +8 more
TL;DR: The authors investigated the pharmacological treatment of delusional depression by assigning patients on a random double-blind basis to amitriptyline alone, perphenazine alone, or a combination of the two.
348